Scientists test tracer to see Cells' 'Battery' in real time
NCT ID NCT07506616
First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 2 times
Summary
This early study tests a new radioactive tracer called 18F-TPP to see if it can map the energy levels inside cells using PET scans. Researchers will study 24 healthy adults to understand how the tracer moves through the body and develop methods to measure cell membrane potential. This is a first step toward better imaging of cell health, not a treatment study.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 18F-TPP (a radioactive tracer for PET imaging)
- What this could lead to
- If successful, this could provide a new way to see cell health in the body, which may help study diseases like heart or brain conditions.
- What could go wrong
- This is a very early Phase 1 study with only 24 healthy volunteers. It is designed to test the imaging method, not to treat any illness, so it may not lead to direct patient benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2033
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Willing and able to give voluntary written informed consent * Stated willingness to comply with all study procedures and availability for the duration of the study * In good general health as evidenced by medical history, physical examination, ECG, serum/urine biochemistry and hematology tests. * If female of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study. Exclusion Criteria: * Know structural heart disease (e.g. myocardial infarction) * Abnormal and clinically significant ECG (as determined by the Investigator or his/her designee) at screening. * Laboratory tests with clinically significant abnormalities at screening * Pregnancy or Lactation * MRI incompatible implants (i.e., such as pacemaker, artificial joints, non-removable body piercings) and other contraindications for MRI, such as claustrophobia, having implanted or embedded metal objects/fragments or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist). * Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits followed by the Yale University PET Center. * Subject who has current, past, or anticipated exposure to radiation in the workplace within one year of the proposed research scans that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits. * Has any condition that, in the opinion of the investigator, would prevent compliance with the study protocol. * Arterial Line Exclusion: Blood donation within eight weeks of the start of the study. * Arterial Line Exclusion: History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto). * Arterial Line Exclusion: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) greater than 5msec above the upper limit of normal. * Arterial Line Exclusion: Unable to safely discontinue or hold aspirin and other NSAID use
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Membrane potential mapping are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Yale University PET Center
RECRUITINGNew Haven, Connecticut, 06510, United States